The trial will initially involve healthy obese people receiving single and multiple escalating doses of the therapy.

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

Arrowhead Pharmaceuticals, Inc. today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic being ...

Adding zilebesiran to a thiazide diuretic or calcium channel blocker may lead to further blood pressure reduction in patients with uncontrolled hypertension. Zilebesiran added to hypertension ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

TransCode Therapeutics (NASDAQ: RNAZ) , has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of A ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

This triggered the development of RNA interference as a tool, and with it came a myriad of investigations into the function of genes. For researchers working with prokaryotes it is now 1998.

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his price target from $400 to $500.

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.